Q32 Bio (QTTB) announced positive 36-week topline results from Part B of the Phase 2a SIGNAL-AA trial, demonstrating the potential of bempikibart, an anti-IL-7Rα antibody, as a treatment for severe and very severe Alopecia Areata. The results support further clinical development, with a registration-directed program planned for the first half of 2027. Sector: Biotechnology Key Highlights: • 35.3% mean reduction in SALT score from baseline (mITT population) • 40.0% of patients achieved a SALT-20 response at Week 36 (mITT) • 30.3% SALT-20 response rate in the overall ITT population • Durable clinical responses observed in some patients even after treatment discontinuation • Favorable safety profile with no serious treatment-related adverse events • Registration-directed clinical program expected to begin in 1H 2027 The positive Phase 2 results reinforce bempikibart's potential as a promising therapy for Alopecia Areata, supporting its advancement toward late-stage clinical development.